Disclosed as part of a presentation at the ESGCT Congress, the data included 74 patient samples that were processed at the time of submission. In line with publicly available data, its PELEUS platform has identified 107 clonal neoantigens in NSCLC samples, 156 in melanoma samples, and 71 in head and neck squamous cell carcinoma samples. The collection of patient material is currently underway across eight sites in the U.K., EU, and the U.S.
https://ir.achillestx.com/static-files/45af6f1b-6d5f-44bc-beb7-ff540e88f0d9
Recent ACHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 11:17:25 AM
- Achilles Therapeutics Announces Strategic Update • GlobeNewswire Inc. • 09/19/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 12:04:13 PM
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/05/2024 08:06:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 11:00:27 AM
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines • GlobeNewswire Inc. • 05/22/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 09:15:57 PM
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 05/17/2024 09:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:44:20 AM
- Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 04/04/2024 10:45:00 AM
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning • GlobeNewswire Inc. • 04/04/2024 10:30:00 AM
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 06:14:13 PM
- Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 09:36:37 PM
- Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/13/2023 09:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2023 09:26:12 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM